Base de dados : MEDLINE
Pesquisa : D04.210.500.745.432.719 [Categoria DeCS]
Referências encontradas : 814 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 82 ir para página                         

  1 / 814 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27261270
[Au] Autor:Damsker JM; Conklin LS; Sadri S; Dillingham BC; Panchapakesan K; Heier CR; McCall JM; Sandler AD
[Ad] Endereço:ReveraGen BioPharma Inc., 155 Gibbs St. Suite 433, Rockville, MD, 20850, USA. Jesse.Damsker@reveragen.com.
[Ti] Título:VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.
[So] Source:Inflamm Res;65(9):737-43, 2016 Sep.
[Is] ISSN:1420-908X
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE AND DESIGN: The goal of this study was to assess the capacity of VBP15, a dissociative steroidal compound, to reduce pro-inflammatory cytokine expression in vitro, to reduce symptoms of colitis in the trinitrobenzene sulfonic acid-induced murine model, and to assess the effect of VBP15 on growth stunting in juvenile mice. MATERIALS: In vitro studies were performed in primary human intestinal epithelial cells. Colitis was induced in mice by administering trinitrobenzene sulfonic acid. Growth stunting studies were performed in wild type outbred mice. TREATMENT: Cells were treated with VBP15 or prednisolone (10 µM) for 24 h. Mice were subjected to 3 days of VBP15 (30 mg/kg) or prednisolone (30 mg/kg) in the colitis study. In the growth stunting study, mice were subjected to VBP15 (10, 30, 45 mg/kg) or prednisolone (10 mg/kg) for 5 weeks. METHODS: Cytokines were measured by PCR and via Luminex. Colitis symptoms were evaluated by assessing weight loss, intestinal blood, and stool consistency. Growth stunting was assessed using an electronic caliper. RESULTS: VBP15 significantly reduced the in vitro production of CCL5 (p < 0.001) IL-6 (p < 0.001), IL-8 (p < 0.05) and reduced colitis symptoms (p < 0.05). VBP15 caused less growth stunting than prednisolone (p < 0.001) in juvenile mice. CONCLUSION: VBP15 may reduce symptoms of IBD, while decreasing or avoiding detrimental side effects.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Colite/tratamento farmacológico
Pregnadienodiois/uso terapêutico
[Mh] Termos MeSH secundário: Animais
Anti-Inflamatórios/farmacologia
Tamanho Corporal/efeitos dos fármacos
Células Cultivadas
Colite/induzido quimicamente
Colite/metabolismo
Citocinas/genética
Citocinas/metabolismo
Modelos Animais de Doenças
Células Epiteliais/efeitos dos fármacos
Células Epiteliais/metabolismo
Feminino
Seres Humanos
Masculino
Camundongos Endogâmicos BALB C
NF-kappa B/metabolismo
Pregnadienodiois/farmacologia
Ácido Trinitrobenzenossulfônico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Cytokines); 0 (NF-kappa B); 0 (Pregnadienediols); 0 (VBP15 compound); 8T3HQG2ZC4 (Trinitrobenzenesulfonic Acid)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170916
[Lr] Data última revisão:
170916
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160605
[St] Status:MEDLINE
[do] DOI:10.1007/s00011-016-0956-8


  2 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27133900
[Au] Autor:Garvin LM; Chen Y; Damsker JM; Rose MC
[Ad] Endereço:Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA; Center for Genetic Medicine Research, Children's National Health System, Washington, DC, USA.
[Ti] Título:A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone.
[So] Source:Pulm Pharmacol Ther;38:17-26, 2016 Jun.
[Is] ISSN:1522-9629
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Overproduction of secretory mucins contributes to morbidity/mortality in inflammatory lung diseases. Inflammatory mediators directly increase expression of mucin genes, but few drugs have been shown to directly repress mucin gene expression. IL-1ß upregulates the MUC5AC mucin gene in part via the transcription factors NFκB while the glucocorticoid Dexamethasone (Dex) transcriptionally represses MUC5AC expression by Dex-activated GR binding to two GRE cis-sites in the MUC5AC promoter in lung epithelial cells. VBP compounds (ReveraGen BioPharma) maintain anti-inflammatory activity through inhibition of NFκB but exhibit reduced GRE-mediated transcriptional properties associated with adverse side-effects and thus have potential to minimize harmful side effects of long-term steroid therapy in inflammatory lung diseases. We investigated VBP15 efficacy as an anti-mucin agent in two types of airway epithelial cells and analyzed the transcription factor activity and promoter binding associated with VBP15-induced MUC5AC repression. VBP15 reduced MUC5AC mRNA abundance in a dose- and time-dependent manner similar to Dex in the presence or absence of IL-1ß in A549 and differentiated human bronchial epithelial cells. Repression was abrogated in the presence of RU486, demonstrating a requirement for GR in the VBP15-induced repression of MUC5AC. Inhibition of NFκB activity resulted in reduced baseline expression of MUC5AC indicating that constitutive activity maintains MUC5AC production. Chromatin immunoprecipitation analysis demonstrated lack of GR and of p65 (NFκB) binding to composite GRE domains in the MUC5AC promoter following VBP15 exposure of cells, in contrast to Dex. These data demonstrate that VBP15 is a novel anti-mucin agent that mediates the reduction of MUC5AC gene expression differently than the classical glucocorticoid, Dex.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Dexametasona/farmacologia
Mucina-5AC/genética
Pregnadienodiois/farmacologia
[Mh] Termos MeSH secundário: Células A549
Anti-Inflamatórios/administração & dosagem
Brônquios/citologia
Brônquios/efeitos dos fármacos
Linhagem Celular
Dexametasona/administração & dosagem
Relação Dose-Resposta a Droga
Células Epiteliais/efeitos dos fármacos
Células Epiteliais/metabolismo
Regulação da Expressão Gênica/efeitos dos fármacos
Glucocorticoides/administração & dosagem
Glucocorticoides/farmacologia
Seres Humanos
Mediadores da Inflamação/metabolismo
Interleucina-1beta/metabolismo
Mucinas/antagonistas & inibidores
Mucinas/metabolismo
Pregnadienodiois/administração & dosagem
RNA Mensageiro/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Glucocorticoids); 0 (Inflammation Mediators); 0 (Interleukin-1beta); 0 (MUC5AC protein, human); 0 (Mucin 5AC); 0 (Mucins); 0 (Pregnadienediols); 0 (RNA, Messenger); 0 (VBP15 compound); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160503
[St] Status:MEDLINE


  3 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26845343
[Au] Autor:Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
[Ad] Endereço:Drug Metabolism and Pharmacokinetics, Clinical Pharmacokinetics/Pharmacodynamics, Novartis Institutes for BioMedical Research, Cambridge, MA, USA. Electronic address: soniya.vaidya@novartis.com.
[Ti] Título:Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
[So] Source:Pulm Pharmacol Ther;37:30-6, 2016 Apr.
[Is] ISSN:1522-9629
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:PURPOSE: QMF149 is a fixed-dose combination of the long-acting ß2 agonist, indacaterol and the corticosteroid, mometasone furoate that is currently under development for treatment of patients with asthma and chronic obstructive pulmonary disease. We describe here a study designed to assess any pharmacokinetic (PK) and/or biopharmaceutical interaction between indacaterol and mometasone furoate when administered via the Breezhaler(®) device, either alone or in a free or fixed combination (QMF149) in healthy adult subjects. METHODS: In this randomized, open-label, four-way crossover study, subjects were randomized to receive indacaterol acetate 150 µg, mometasone furoate 320 µg, alone and as free combination of the individual components, or QMF149 (indacaterol acetate 150 µg/mometasone furoate 320 µg) once daily for 14 days in each period, followed by a 7-day washout between periods. PK profiles were characterized on Day 14 up to 168 h post-dose. RESULTS: Indacaterol AUC0-24h,ss and Cmax,ss after administration of QMF149 were 13% [ratio: 1.13; 90%CI: 1.09, 1.17] and 18% [ratio: 1.18; 90%CI: 1.12, 1.25] higher, respectively, than indacaterol monotherapy. Mometasone furoate AUC0-24h,ss and Cmax,ss after administration of QMF149 were 14% [ratio: 1.14; 90%CI: 1.09, 1.20] and 19% [ratio: 1.19; 90%CI: 1.13, 1.26], higher, respectively than mometasone furoate monotherapy. The majority (three of four comparisons between QMF149 and monotherapy) of the 90% confidence intervals of the between-treatment ratios for AUC0-24h,ss and Cmax,ss were within the 0.80 to 1.25 interval and therefore fulfilled bioequivalence criteria. The 90% confidence interval for Cmax,ss for MF for the QMF149 vs. monotherapy comparison was [1.13, 1.26]. Although no definitive data can be provided on the basis of the present study results, it is unlikely that the small observed differences in expsoure are clinically meaningful. Multiple inhaled doses of indacaterol and mometasone furoate, when administered alone, in free combination or as QMF149 were well tolerated. CONCLUSIONS: The QMF149 fixed dose combination treatment showed comparable systemic exposure to the free combination and monotherapy treatments in terms of AUC0-24h,ss and Cmax,ss for both indacaterol and mometasone furoate, indicating an absence of clinically relevant PK or biopharmaceutical interactions. These data support further development of QMF149 without dose adjustment.
[Mh] Termos MeSH primário: Corticosteroides/farmacocinética
Agonistas de Receptores Adrenérgicos beta 2/farmacocinética
Indanos/farmacocinética
Pregnadienodiois/farmacocinética
Quinolonas/farmacocinética
[Mh] Termos MeSH secundário: Administração por Inalação
Corticosteroides/administração & dosagem
Agonistas de Receptores Adrenérgicos beta 2/administração & dosagem
Adulto
Área Sob a Curva
Estudos Cross-Over
Combinação de Medicamentos
Interações Medicamentosas
Feminino
Seres Humanos
Indanos/administração & dosagem
Masculino
Furoato de Mometasona/administração & dosagem
Furoato de Mometasona/farmacocinética
Pregnadienodiois/administração & dosagem
Quinolonas/administração & dosagem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Adrenergic beta-2 Receptor Agonists); 0 (Drug Combinations); 0 (Indans); 0 (Pregnadienediols); 0 (QMF149); 0 (Quinolones); 04201GDN4R (Mometasone Furoate); 8OR09251MQ (indacaterol)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160205
[St] Status:MEDLINE


  4 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:26543929
[Au] Autor:Shah SA
[Ti] Título:Response.
[So] Source:Allergy Asthma Proc;36(5):e104-5, 2015 Sep-Oct.
[Is] ISSN:1539-6304
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antialérgicos/administração & dosagem
Antialérgicos/farmacocinética
Sprays Nasais
Pregnadienodiois/administração & dosagem
Pregnadienodiois/farmacocinética
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Nasal Sprays); 0 (Pregnadienediols)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151107
[St] Status:MEDLINE


  5 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26511361
[Au] Autor:Freishtat RJ; Nino G; Tsegaye Y; Alcala SE; Benton AS; Watson AM; Reeves EK; Haider SK; Damsker JM
[Ad] Endereço:Division of Emergency Medicine, Children's National Health System, Washington, DC, USA. rfreishtat@childrensnational.org.
[Ti] Título:Pharmacologically-induced mitotic synchrony in airway epithelial cells as a mechanism of action of anti-inflammatory drugs.
[So] Source:Respir Res;16:132, 2015 Oct 29.
[Is] ISSN:1465-993X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Mitotic synchrony is the synchronous progression of a population of cells through the cell cycle and is characteristic of non-diseased airway epithelial cells. However, we previously showed that asthmatic airway epithelial cells are characterized by mitotic asynchrony and are pro-inflammatory as a result. Glucocorticoids can induce mitotic synchrony that in turn suppresses the pro-inflammatory state of diseased cells, suggesting a novel anti-inflammatory mechanism of action. Herein, we benchmarked traditional glucocorticoids against the ability of a new clinical-stage dissociative steroidal drug, VBP15, for mitotic resynchronization and associated anti-inflammatory activity in asthmatic airway epithelial cells. METHODS: Primary airway epithelial cells differentiated at air-liquid interface were exposed to VBP15, dexamethasone or vehicle following in vitro mechanical injury. Basolateral cytokine secretions (TGF-ß1, IL-6, IL-10, IL-13, and IL-1ß) were analyzed at different time points using cytometric bead assays and mitosis was examined by flow cytometry. RESULTS: VBP15 improved mitotic synchrony of proliferating asthmatic cells in air-liquid interface cultures compared to vehicle-exposed cultures. VBP15 also significantly reduced the basolateral secretion of pro-inflammatory (i.e. IL-1ß) and pro-fibrogenic cytokines (i.e. TGF-ß1) in air-liquid interface-differentiated asthmatic epithelial cultures following mechanical injury. CONCLUSION: VBP15 improves mitotic asynchrony and injury-induced pro-inflammatory and fibrogenic responses in asthmatic airway epithelial cultures with efficacy comparable to traditional glucocorticoids. As it is predicted to show superior side effect profiles compared to traditional glucocorticoids, VBP15 holds potential for treatment of asthma and other respiratory conditions.
[Mh] Termos MeSH primário: Anti-Inflamatórios/farmacologia
Asma/tratamento farmacológico
Dexametasona/farmacologia
Células Epiteliais/efeitos dos fármacos
Glucocorticoides/farmacologia
Pulmão/efeitos dos fármacos
Mitose/efeitos dos fármacos
Pregnadienodiois/farmacologia
[Mh] Termos MeSH secundário: Asma/metabolismo
Asma/patologia
Estudos de Casos e Controles
Células Cultivadas
Citocinas/metabolismo
Células Epiteliais/patologia
Seres Humanos
Mediadores da Inflamação/metabolismo
Pulmão/metabolismo
Pulmão/patologia
Fibrose Pulmonar/metabolismo
Fibrose Pulmonar/patologia
Fibrose Pulmonar/prevenção & controle
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Cytokines); 0 (Glucocorticoids); 0 (Inflammation Mediators); 0 (Pregnadienediols); 0 (VBP15 compound); 7S5I7G3JQL (Dexamethasone)
[Em] Mês de entrada:1607
[Cu] Atualização por classe:161019
[Lr] Data última revisão:
161019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151030
[St] Status:MEDLINE
[do] DOI:10.1186/s12931-015-0293-4


  6 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26314812
[Au] Autor:Djupesland PG; Mahmoud RA
[Ti] Título:Letter to the Editor: Incorrect conclusions regarding deposition of conventional mometasone furoate (MF) nasal spray.
[So] Source:Allergy Asthma Proc;36(5):e104, 2015 Sep-Oct.
[Is] ISSN:1539-6304
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Antialérgicos/administração & dosagem
Antialérgicos/farmacocinética
Sprays Nasais
Pregnadienodiois/administração & dosagem
Pregnadienodiois/farmacocinética
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Anti-Allergic Agents); 0 (Nasal Sprays); 0 (Pregnadienediols)
[Em] Mês de entrada:1511
[Cu] Atualização por classe:161020
[Lr] Data última revisão:
161020
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150829
[St] Status:MEDLINE
[do] DOI:10.2500/aap.2015.36.3868


  7 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26084823
[Au] Autor:Aksoy F; Dogan R; Kocak I; Veyseller B; Ozturan O; Incir S
[Ad] Endereço:Bezmialem Vakif University, Department of Otorhinolaryngology, Fatih, Istanbul, Turkey.
[Ti] Título:Effect of Nasal Corticosteroid on Secretory Immunoglobulin A Measured in Rat Nasal Lavage: Experimental Study.
[So] Source:Otolaryngol Head Neck Surg;153(2):298-301, 2015 Aug.
[Is] ISSN:1097-6817
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: In this study, we aimed to experimentally investigate the effects of nasal corticosteroids on the levels of secretory immunoglobulin A (sIgA) in nasal mucosa in rats. STUDY DESIGN: Prospective, randomized control trial. SETTING: Research laboratory. SUBJECT AND METHODS: Twenty-four male Sprague Dawley rats were included in our study. The rats were randomized into 3 groups. In group 1, nasal mometasone furoate was applied to the rats for 30 days. Saline was applied to group 2 for 30 days. Group 3 was the control group and received no treatment throughout the study period. Nasal lavage was conducted on both nasal openings of all rats in the 3 groups at the beginning of the study and on days 15 and 30, and the lavage solution (distilled water) was collected by aspiration. RESULTS: In group 1, the sIgA value was significantly higher at day 15 than at baseline. No significant difference was found between the sIgA values on day 15 and day 30. In groups 2 and 3, there were no significant differences in sIgA values at baseline, day 15, and day 30. The sIgA value of group 1 on day 15 was significantly higher than the values of groups 2 and 3. The sIgA value of group 1 on day 30 was significantly higher than the values of groups 2 and 3. CONCLUSION: Topical corticosteroids (mometasone furoate) applied to the nasal mucosa significantly increase nasal sIgA levels.
[Mh] Termos MeSH primário: Corticosteroides/administração & dosagem
Imunoglobulina A Secretora/análise
Pregnadienodiois/administração & dosagem
Pregnadienodiois/farmacologia
[Mh] Termos MeSH secundário: Administração Intranasal
Animais
Masculino
Furoato de Mometasona
Lavagem Nasal
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Immunoglobulin A, Secretory); 0 (Pregnadienediols); 04201GDN4R (Mometasone Furoate)
[Em] Mês de entrada:1510
[Cu] Atualização por classe:151119
[Lr] Data última revisão:
151119
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150619
[St] Status:MEDLINE
[do] DOI:10.1177/0194599815589073


  8 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25964172
[Au] Autor:Yilmaz HB
[Ad] Endereço:Dr. Lutfi Kirdar Kartal Education and Research Hospital, Otolaryngology Clinic, Istanbul-Turkey. Electronic address: drbakiyilmaz@gmail.com.
[Ti] Título:Allergic rhinitis in children with adenoidal hypertrophy and otitis media with effusion.
[So] Source:Am J Otolaryngol;36(4):617-8, 2015 Jul-Aug.
[Is] ISSN:1532-818X
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Tonsila Faríngea/patologia
Anti-Inflamatórios/administração & dosagem
Sprays Nasais
Otite Média com Derrame/tratamento farmacológico
Pregnadienodiois/administração & dosagem
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Nasal Sprays); 0 (Pregnadienediols)
[Em] Mês de entrada:1508
[Cu] Atualização por classe:150615
[Lr] Data última revisão:
150615
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:150513
[St] Status:MEDLINE


  9 / 814 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25959672
[Au] Autor:Lipworth B
[Ad] Endereço:Scottish Centre for Respiratory Research, Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, United Kingdom. Electronic address: b.j.lipworth@dundee.ac.uk.
[Ti] Título:Nasal endoscopy to characterize sinonasal disease.
[So] Source:J Allergy Clin Immunol;136(1):212, 2015 Jul.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Asma/tratamento farmacológico
Seios Paranasais/efeitos dos fármacos
Pregnadienodiois/uso terapêutico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Pregnadienediols)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:150512
[St] Status:MEDLINE


  10 / 814 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:25959669
[Au] Autor:Dixon AE; Castro M; Cohen RI; Gerald LB; Holbrook JT; Irvin CG; Mohapatra S; Peters SP; Rayapudi S; Sugar EA; Wise RA; American Lung Association­Asthma Clinical Research Centers
[Ad] Endereço:Department of Medicine, University of Vermont, Burlington, Vt. Electronic address: Anne.Dixon@uvm.edu.
[Ti] Título:Reply: To PMID 25174863.
[So] Source:J Allergy Clin Immunol;136(1):212-3, 2015 Jul.
[Is] ISSN:1097-6825
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Asma/tratamento farmacológico
Seios Paranasais/efeitos dos fármacos
Pregnadienodiois/uso terapêutico
[Mh] Termos MeSH secundário: Feminino
Seres Humanos
Masculino
[Pt] Tipo de publicação:COMMENT; LETTER; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Pregnadienediols)
[Em] Mês de entrada:1509
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:150512
[St] Status:MEDLINE



página 1 de 82 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde